{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:15:45Z","timestamp":1785528945258,"version":"3.56.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T00:00:00Z","timestamp":1673654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T00:00:00Z","timestamp":1673654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract\u00a0<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The aim of this study was to evaluate the safety and efficacy of the Fantom BRS 6\u00a0months after implantation using the optical coherence tomography (OCT) imaging.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Twenty STEMI patients treated with a sirolimus\u2010eluting Fantom BRS were enrolled into a prospective, single-arm, serial observational study. The scaffold sizing, positioning and optimisation were guided by OCT imaging. The primary endpoint was device\u2010orientated composite endpoints (DOCE), comprised of cardiac death, target-vessel-related myocardial infarction and target lesion failure. To evaluate the device performance at the scaffold level, we performed a quantitative coronary angiography (QCA) and OCT imaging at 6\u00a0months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The primary endpoint did not occur in any patient within the 6-month follow\u2010up. There were no major adverse cardiac events (MACEs) or DOCEs, no cases of scaffold thrombosis, target lesion revascularization and no deaths. In QCA, we observed a decrease in the minimum and mean lumen diameter in the in-scaffold region and in the proximal and distal peri-scaffold region. Similarly, the minimum lumen area and reference vessel diameter had decreased in both QCA and OCT. The OCT imaging showed improvement in the expansion index and malposition rate.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>A serial 6-month OCT imaging after implantation of a third-generation Tyrocore-based bioresorbable coronary scaffold indicated good coverage of the struts with excellent healing of the scaffold, low neointima growth and no signs of neoatherosclerosis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10557-023-07429-0","type":"journal-article","created":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T07:02:44Z","timestamp":1673679764000},"page":"719-729","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Third-Generation Sirolimus\u2010Eluting Bioresorbable Tyrocore Scaffold Implantation in Patients with ST\u2010Segment Elevation Myocardial Infarction: Baseline and 6-Month OCT and Clinical Outcomes\u2014a FANTOM STEMI Pilot Study"],"prefix":"10.1007","volume":"38","author":[{"given":"Lukasz","family":"Koltowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariusz","family":"Tomaniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Ochijewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz","family":"Opolski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janusz","family":"Kochman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,14]]},"reference":[{"issue":"10096","key":"7429_CR1","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S0140-6736(17)31470-8","volume":"390","author":"ZA Ali","year":"2017","unstructured":"Ali ZA, Serruys PW, Kimura T, Gao R, Ellis SG, Kereiakes DJ, Onuma Y, Simonton C, Zhang Z, Stone GW. 2-year outcomes with the absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy. Lancet. 2017;390(10096):760\u201372.","journal-title":"Lancet"},{"issue":"13","key":"7429_CR2","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.4244\/EIJ-D-17-00873","volume":"13","author":"B Chevalier","year":"2018","unstructured":"Chevalier B, Cequier A, Dudek D, Haude M, Carrie D, Sabate M, Windecker S, Reith S, de Sousa Almeida M, Campo G, Iniguez A, Onuma Y, Serruys PW. Four-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II Trial). EuroIntervention. 2018;13(13):1561\u20134.","journal-title":"EuroIntervention"},{"issue":"11","key":"7429_CR3","doi-asserted-by":"publisher","first-page":"e938","DOI":"10.4244\/EIJ-D-20-00024","volume":"16","author":"Y Onuma","year":"2020","unstructured":"Onuma Y, Chevalier B, Ono M, Cequier A, Dudek D, Haude M, Carrie D, Sabate M, Windecker S, Rapoza RR, West NEJ, Reith S, de Sousa Almeida M, Campo G, Iniguez-Romo A, Serruys PW. Bioresorbable scaffolds versus everolimus-eluting metallic stents: five-year clinical outcomes of the randomised ABSORB II trial. EuroIntervention. 2020;16(11):e938\u201341.","journal-title":"EuroIntervention"},{"issue":"9962","key":"7429_CR4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0140-6736(14)61455-0","volume":"385","author":"PW Serruys","year":"2015","unstructured":"Serruys PW, Chevalier B, Dudek D, Cequier A, Carrie D, Iniguez A, Dominici M, van der Schaaf RJ, Haude M, Wasungu L, Veldhof S, Peng L, Staehr P, Grundeken MJ, Ishibashi Y, Garcia-Garcia HM, Onuma Y. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet. 2015;385(9962):43\u201354.","journal-title":"Lancet"},{"issue":"3","key":"7429_CR5","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","volume":"41","author":"J Knuuti","year":"2020","unstructured":"Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ, E.S.C.S.D. Group. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407\u201377.","journal-title":"Eur Heart J"},{"issue":"11","key":"7429_CR6","doi-asserted-by":"publisher","first-page":"e913","DOI":"10.4244\/EIJ-D-20-00198","volume":"16","author":"J Gomez-Lara","year":"2020","unstructured":"Gomez-Lara J, Ortega-Paz L, Brugaletta S, Cuesta J, Romani S, Serra A, Salinas P, Garcia Del Blanco B, Goicolea J, Hernandez-Antolin R, Antuna P, Romaguera R, Regueiro A, Rivero F, Cequier A, Alfonso F, Gomez-Hospital JA, Sabate M. Collaborators, Bioresorbable scaffolds versus permanent sirolimus-eluting stents in patients with ST-segment elevation myocardial infarction: vascular healing outcomes from the MAGSTEMI trial. EuroIntervention. 2020;16(11):e913\u201321.","journal-title":"EuroIntervention"},{"issue":"35","key":"7429_CR7","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1093\/eurheartj\/ehw196","volume":"37","author":"M Haude","year":"2016","unstructured":"Haude M, Ince H, Abizaid A, Toelg R, Lemos PA, von Birgelen C, Christiansen EH, Wijns W, Neumann FJ, Kaiser C, Eeckhout E, Lim ST, Escaned J, Onuma Y, Garcia-Garcia HM, Waksman R. Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial. Eur Heart J. 2016;37(35):2701\u20139.","journal-title":"Eur Heart J"},{"issue":"18","key":"7429_CR8","doi-asserted-by":"publisher","first-page":"e2201","DOI":"10.4244\/EIJ-D-17-00311","volume":"13","author":"J Kochman","year":"2018","unstructured":"Kochman J, Koltowski L, Tomaniak M, Jakala J, Proniewska K, Legutko J, Roleder T, Piertrasik A, Rdzanek A, Kochman W, Brugaletta S, Opolski G, Regar E. First serial optical coherence tomography assessment at baseline, 12 and 24 months in STEMI patients treated with the second-generation absorb bioresorbable vascular scaffold. EuroIntervention. 2018;13(18):e2201\u20139.","journal-title":"EuroIntervention"},{"key":"7429_CR9","unstructured":"Leibundgut G. A novel, radiopaque, bioresorbable tyrosine-derived polymer for cardiovascular scaffolds, cardiac interventions today, vol., no 2018, p. European Featured Technology. 2018. Available online: https:\/\/citoday.com\/articles\/2018-july-aug\/a-novel-radiopaque-bioresorbable-tyrosine-derived-polymer-for-cardiovascular-scaffolds?c4src=archive:feed. Accessed 29 Feb\u00a02020."},{"key":"7429_CR10","doi-asserted-by":"crossref","unstructured":"Lutz M, Anderson J, Abizaid A, et al. TCT CONNECT-270 FANTOM II Trial: Safety and performance study of the fantom sirolimus-eluting bioresorbable coronary scaffold\u2014first report: 4-year clinical outcomes. J Am Coll Cardiol. 2020;76(17 Supplement S):B118.","DOI":"10.1016\/j.jacc.2020.09.287"},{"issue":"4","key":"7429_CR11","doi-asserted-by":"publisher","first-page":"501","DOI":"10.4244\/EIJV9I4A80","volume":"9","author":"T Kajiya","year":"2013","unstructured":"Kajiya T, Liang M, Sharma RK, Lee CH, Chan MY, Tay E, Chan KH, Tan HC, Low AF. Everolimus-eluting bioresorbable vascular scaffold (BVS) implantation in patients with ST-segment elevation myocardial infarction (STEMI). EuroIntervention. 2013;9(4):501\u20134.","journal-title":"EuroIntervention"},{"issue":"1","key":"7429_CR12","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1002\/ccd.28414","volume":"96","author":"L Koltowski","year":"2020","unstructured":"Koltowski L, Tomaniak M, Ochijewicz D, Maksym J, Roleder T, Zaleska M, Proniewska K, Opolski G, Kochman J. Second generation, sirolimus-eluting, bioresorbable Tyrocore scaffold implantation in patients with ST-segment elevation myocardial infarction: baseline OCT and 30-day clinical outcomes - A FANTOM STEMI pilot study. Catheter Cardiovasc Interv. 2020;96(1):E1\u20137.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"17","key":"7429_CR13","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","volume":"115","author":"DE Cutlip","year":"2007","unstructured":"Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW, C Academic research. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344\u201351.","journal-title":"Circulation"},{"issue":"9667","key":"7429_CR14","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/S0140-6736(09)60325-1","volume":"373","author":"PW Serruys","year":"2009","unstructured":"Serruys PW, Ormiston JA, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia HM, Nieman K, Bruining N, Dorange C, Miquel-Hebert K, Veldhof S, Webster M, Thuesen L, Dudek D. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet. 2009;373(9667):897\u2013910.","journal-title":"Lancet"},{"issue":"7","key":"7429_CR15","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1161\/01.CIR.0000116751.88818.10","volume":"109","author":"MK Hong","year":"2004","unstructured":"Hong MK, Mintz GS, Lee CW, Kim YH, Lee SW, Song JM, Han KH, Kang DH, Song JK, Kim JJ, Park SW, Park SJ. Incidence, mechanism, predictors, and long-term prognosis of late stent malapposition after bare-metal stent implantation. Circulation. 2004;109(7):881\u20136.","journal-title":"Circulation"},{"issue":"2","key":"7429_CR16","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1253\/circj.CJ-14-1398","volume":"79","author":"G Scalone","year":"2015","unstructured":"Scalone G, Brugaletta S, Gomez-Monterrosas O, Otsuki S, Sabate M. ST-segment elevation myocardial infarction - ideal scenario for bioresorbable vascular scaffold implantation? Circ J. 2015;79(2):263\u201370.","journal-title":"Circ J"},{"issue":"3","key":"7429_CR17","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1093\/eurheartj\/ehv500","volume":"37","author":"M Sabate","year":"2016","unstructured":"Sabate M, Windecker S, Iniguez A, Okkels-Jensen L, Cequier A, Brugaletta S, Hofma SH, Raber L, Christiansen EH, Suttorp M, Pilgrim T, Anne van Es G, Sotomi Y, Garcia-Garcia HM, Onuma Y, Serruys PW. Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial. Eur Heart J. 2016;37(3):229\u201340.","journal-title":"Eur Heart J"},{"issue":"18","key":"7429_CR18","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1016\/j.jcin.2017.07.033","volume":"10","author":"A Abizaid","year":"2017","unstructured":"Abizaid A, Carrie D, Frey N, Lutz M, Weber-Albers J, Dudek D, Chevalier B, Weng SC, Costa RA, Anderson J, Stone GW, Investigators FIC. 6-month clinical and angiographic outcomes of a novel radiopaque sirolimus-eluting bioresorbable vascular scaffold: the FANTOM II study. JACC Cardiovasc Interv. 2017;10(18):1832\u20138.","journal-title":"JACC Cardiovasc Interv"},{"issue":"1","key":"7429_CR19","doi-asserted-by":"publisher","first-page":"e000941","DOI":"10.1136\/openhrt-2018-000941","volume":"6","author":"JK Simonsen","year":"2019","unstructured":"Simonsen JK, Holck EN, Carrie D, Frey N, Lutz M, Weber-Albers J, Dudek D, Chevalier B, Daemen J, Dijkstra J, Fox Maule C, Neghabat O, Lassen JF, Anderson J, Christiansen EH, Abizaid A, Holm NR. Mechanical performance and healing patterns of the novel sirolimus-eluting bioresorbable Fantom scaffold: 6-month and 9-month follow-up by optical coherence tomography in the FANTOM II study. Open Heart. 2019;6(1):e000941.","journal-title":"Open Heart"},{"issue":"36","key":"7429_CR20","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1093\/eurheartj\/ehy436","volume":"39","author":"T Asano","year":"2018","unstructured":"Asano T, Serruys PW, Collet C, Miyazaki Y, Takahashi K, Chichareon P, Katagiri Y, Modolo R, Tenekecioglu E, Morel MA, Garg S, Wykrzykowska J, Piek JJ, Sabate M, Morice MC, Chevalier B, Windecker S, Onuma Y. Angiographic late lumen loss revisited: impact on long-term target lesion revascularization. Eur Heart J. 2018;39(36):3381\u20139.","journal-title":"Eur Heart J"},{"issue":"18","key":"7429_CR21","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1161\/01.CIR.0000128850.84227.FD","volume":"109","author":"E Grube","year":"2004","unstructured":"Grube E, Sonoda S, Ikeno F, Honda Y, Kar S, Chan C, Gerckens U, Lansky AJ, Fitzgerald PJ. Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation. 2004;109(18):2168\u201371.","journal-title":"Circulation"},{"issue":"1","key":"7429_CR22","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1161\/01.CIR.0000047700.58683.A1","volume":"107","author":"E Grube","year":"2003","unstructured":"Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, Russell ME. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation. 2003;107(1):38\u201342.","journal-title":"Circulation"},{"issue":"8","key":"7429_CR23","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1161\/CIRCULATIONAHA.105.591206","volume":"114","author":"J Fajadet","year":"2006","unstructured":"Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Munzel T, Popma JJ, Fitzgerald PJ, Bonan R, Kuntz RE, Investigators EI. Randomized, double-blind, multicenter study of the endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation. 2006;114(8):798\u2013806.","journal-title":"Circulation"},{"issue":"4","key":"7429_CR24","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.jjcc.2016.06.013","volume":"69","author":"T Sato","year":"2017","unstructured":"Sato T, Jose J, El-Mawardy M, Sulimov DS, T\u00f6lg R, Richardt G, Abdel-Wahab M. Relationship between peri-strut low intensity areas and vascular healing response after everolimus-eluting bioresorbable scaffold implantation: an optical coherence tomography study. J Cardiol. 2017;69(4):606\u201312.","journal-title":"J Cardiol"},{"issue":"10","key":"7429_CR25","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.3324\/haematol.2009.009134","volume":"94","author":"CM Lucas","year":"2009","unstructured":"Lucas CM, Harris RJ, Giannoudis A, Davies A, Knight K, Watmough SJ, Wang L, Clark RE. Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript. Haematologica. 2009;94(10):1362\u20137.","journal-title":"Haematologica"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-023-07429-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-023-07429-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-023-07429-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T02:23:44Z","timestamp":1721787824000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-023-07429-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,14]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["7429"],"URL":"https:\/\/doi.org\/10.1007\/s10557-023-07429-0","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,14]]},"assertion":[{"value":"4 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The local ethics committee approved the study protocol. This study was performed in line with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"\u0141ukasz Ko\u0142towski received research grants and speaker\u2019s fees from Reva Medical and speaker\u2019s fees from Abbott. All other authors have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}